Presentations
Simulation study on methods for ordinal data in central statistical monitoring and their application on the German Multiple Sclerosis Register
Fneish F, Ellenberger D et al., 30. September 2026; ISCB-GMDS Freiburg i.B. 2026
Best practices in MS and rare disease registries (youtube)
Stahmann A, 24. April 2026; Annual Conference EMSP 2026 - Berlin
Symptom-related risk factors for early retirement in multiple sclerosis patients with low disability and disease duration under 15 years
Kirstein M, Craig E, Frahm N, Peters M et al.; ECTRIMS 2025 - Barcelona; Type: Adobe/PDF
Real-world data on the prevalence and therapy of symptomatic bladder and bowel dysfunction in people with multiple sclerosis
Frahm N et al., veröffentlicht: September 2024; ECTRIMS - Kopenhagen; Type: Adobe/PDF
Influence of disease modifying therapies on expanded disability status scale scores trajectories in treated and not-treated patients with secondary Progressive multiple sclerosis - analysis from nine registries (Abstract)
L. Pontieri et al, 2022: Vortrag auf der ECTRIMS 2022, Amsterdam
Validation of three Secondary Progressive Multiple Sclerosis classification methods in five registries within the SPMS Research Collaboration Network (Abstract), deutsche Layperson-Version
L. Forsberg, D. Ellenberger, A. Stahmann, et al, 2020: Vortrag auf dem Virtual Joint ACTRIMS-ECTRIMS meeting 2020 (MS Virtual 2020), PS05 - Pharmacological management of progressive MS, deutsche Layperson-Version veröffentlicht im Dezember 2020 in der aktiv! Nr. 269 Seite 32 f., Type: Adobe/PDF
Ongoing disease modifying treatment associated with mis-classification of secondary progressive as relapsing-remitting multiple sclerosis (Abstract),
deutsche Layperson-Version
J. Hillert, D. Ellenberger, A. Stahmann, et al, 2020: Vortrag auf dem Virtual Joint ACTRIMS-ECTRIMS meeting 2020 (MS Virtual 2020), PS05 - Pharmacological management of progressive MS, deutsche Layperson-Version veröffentlicht im Dezember 2020 in der aktiv! Nr. 269 Seite 32 f., Type: Adobe/PDF
First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are associated with worse COVID-19 Outcomes (Abstract)
S. Simpson-Yap, A. Stahmann, et al, 2020: Vortrag auf dem Virtual Joint ACTRIMS-ECTRIMS meeting 2020 (MS Virtual 2020), SS02 - Special Session: COVID-19
Variation in Time to First Disease Modifying Therapy in people with MS in the United States, United Kingdom, and Germany
Als Vortrag für die AAN 2020 vorgesehen, Kongress wurde aufgrund der Corona-Pandemie abgesagt.
Abstract A Stahmann, et al, 2020: Neurology, April 14, 2020; 94 (15 Supplement) (517)
Variation in time to first DMT among people with MS in the United States, United Kingdom and Germany (Abstract), deutsche Layperson-Version
Stahmann et al, 2019: Vortrag auf der EAN 2019, Oslo; deutsche Layperson-Version veröffentlicht im September 2019 in der aktiv! Nr. 264 Seite 33, Type: Adobe/PDF
Multiple sclerosis in Germany 2018 - update on baseline data from the German MS Registry (Abstract)
Flachenecker et al, 2018: Vortrag auf der ECTRIMS 2018, Berlin